Daniëlle van der Waal, PhD, is a senior epidemiologist and quality assurance coordinator at the Dutch Expert Centre for Screening (LRCB). She holds a master’s degree in Biomedical Sciences and completed a PhD at Radboud University Medical Center (Nijmegen, the Netherlands), focusing on mammographic density and breast cancer detection. With extensive experience in large-scale epidemiological studies, she previously served as the coordinator of the Personalised RISk-based MAmmascreening study (PRISMA) study, which explores risk-based breast cancer screening. Currently, her work is dedicated to improving cancer screening through research, national and international audits, and training radiographers and radiologists.

Chelsea Saia, MPH, is a Senior Health Data Manager at the University of Pennsylvania's Perelman School of Medicine in the United States. With over a decade of experience in health data analytics, she focuses on optimizing cancer screening and healthcare delivery research, as well as advancing community health data initiatives. Ms. Saia has managed real-world evidence analytics at a consulting firm and served as an Epidemiologist for the Virginia Department of Health and Navy and Marine Corps Public Health Center. She holds a Bachelor's degree from Virginia Tech and a Master's in Public Health Epidemiology from Eastern Virginia Medical School.

Dr. Meza is Distinguished Scientist at BC Cancer and Professor at the UBC School of Population and Public Health. He has a PhD in Applied Mathematics from the University of Washington. Prior to joining BC Cancer, Dr. Meza was Professor of Epidemiology at the University of Michigan. Dr. Meza’s research focuses on lung cancer screening, tobacco control, and lung cancer epidemiology and prevention. He is principal investigator of the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Working Group and of the Center for the Assessment of Tobacco Regulations (CAsToR).

Ulrike Haug, a professor at Bremen University, is deputy scientific director of the Leibniz Institute for Prevention Research and Epidemiology – BIPS and heads the department Clinical Epidemiology at BIPS. She has a strong research focus on cancer screening and conducted multiple types of studies on cancer screening (particularly colorectal and breast cancer). She holds the scientific responsibility for the GePaRD database covering health claims from 20% of the German population. She is a member of national and international committees in the field of cancer prevention and screening, e.g. of the National Decade Against Cancer and the World Endoscopy Organization.

Hormuzd Katki is a Senior Investigator in the Biostatistics Branch of the US National Cancer Institute. Dr. Katki’s research focus is on methodology and development of prediction models for use in all aspects of screening, with a primary focus in lung and cervical screening. He is also works in multicancer early detection, projecting outcomes from hypothetical screening trials or real-world screening, and quantifying racial/ethnic disparities in screening.

I have a background (BSc, MSc and Master's degree) in quantitative finance and two years of professional experience at the European Central Bank. Currently, as a PhD candidate at Erasmus MC, my research focuses on various aspects of cancer screening. This includes evaluating the impact and performance of screening programmes over time, modeling country-specific cancer programmes, conducting cost-effectiveness analyses aimed at optimizing existing screening programmes, and developing new screening programmes.

Dr Adam Brentnall is a Statistician from Barts Clinical Trials Unit, Wolfson Institute of Population Health, Queen Mary University of London (QMUL). He also works closely with the CRUK and QMUL Cancer Prevention Trials Unit. He is currently a member of the UK National Screening Committee research and Methodology group, and the CRUK Expert Review Panel on Early Detection & Diagnosis Trials, Behavioural, Health Systems and Health Economics Research. He recently served as statistician on a National Institute of Clinical Excellence (NICE) committee for guidelines on identifying and managing familial and genetic risk for ovarian cancer.